New vaccine aims to boost immunity against breast cancer recurrence
NCT ID NCT04270149
First seen Feb 28, 2026 · Last updated May 15, 2026 · Updated 11 times
Summary
This early-phase study tests a peptide vaccine designed to help the immune system recognize and fight estrogen receptor-positive (ER+) breast cancer cells. Eight participants who have completed standard treatments receive the vaccine alongside immune-boosting agents. The main goal is to check safety and measure immune responses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
Conditions
Explore the condition pages connected to this study.